Yaming Li, M.M.

Haisco Pharmaceutical Group Co, Ltd.
Chengdu, China (People's Republic)

Disclosure information not submitted.

Presentation(s):

• MON-650 - Enhanced Efficacy of Crisugabalin 80 Mg/D in Diabetic Peripheral Neuropathic Pain Patients with BMI ≥25 Kg/M²Or Longer Disease Duration: A Post-Hoc Analysis

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-651 - High-Dose Crisugabalin Significantly Improving the Pain Symptoms in Patients with Diabetic Peripheral Neuropathic Pain (DPNP)

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT